Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

by Annemieke Witteveen, Annemiek B G Kwast, Gabe S Sonke, Maarten J IJzerman, Sabine Siesling
Published 2015-01-01

Letter regarding Zhao et al. entitled “ gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia”

by Maarten J Deenen, Linda M Henricks, Gabe S Sonke, Jan HM Schellens, Didier Meulendijks
Published 2017-05-01

The facilitating role of chemotherapy in the palliative phase of cancer: qualitative interviews with advanced cancer patients.

by Hilde M Buiting, Wim Terpstra, Floriske Dalhuisen, Nicolette Gunnink-Boonstra, Gabe S Sonke, Govert den Hartogh
Published 2013-01-01

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer

by Marianne J. Rutten, Gabe S. Sonke, Anneke M. Westermann, Willemien J. van Driel, Johannes W. Trum, Gemma G. Kenter, Marrije R. Buist
Published 2015-01-01

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer

by Mette S. van Ramshorst, Suzana C. Teixeira, Bas B. Koolen, Kenneth E. Pengel, Kenneth G. Gilhuijs, Jelle Wesseling, Sjoerd Rodenhuis, Renato A. Valdés Olmos, Emiel J. Rutgers, Wouter V. Vogel, Gabe S. Sonke, Marie-Jeanne T. Vrancken Peeters
Published 2017-05-01

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

by Alexander M Th Schmitz, Suzana C Teixeira, Kenneth E Pengel, Claudette E Loo, Wouter V Vogel, Jelle Wesseling, Emiel J Th Rutgers, Renato A Valdés Olmos, Gabe S Sonke, Sjoerd Rodenhuis, Marie Jeanne T F D Vrancken Peeters, Kenneth G A Gilhuijs
Published 2017-01-01